Zdravljenje žensk z multiplo sklerozo, ki načrtujejo družino

slovenian

2024

Narodna in univerzitetna knjižnica
(Obvezni izvod spletne publikacije)

In the past, women with multiple sclerosis were discouraged from becoming pregnant because of the misconception that it could worsen the course of their disease. However, more recent studies show a reduction in the risk of worsening of the disease during pregnancy and after childbirth if treatment is properly planned and implemented without adversely affecting the health of the mother or the baby. When planning a pregnancy, it is also important to consider the risk to the baby from possible exposure to the drugs and the risk to the mother from relapse. Recent studies have confirmed the safety of injectable drugs such as glatiramer acetate and interferon-beta during pregnancy while some oral drugs may pose a risk to the foetus. Monoclonal antibodies such as rituximab or natalizumab are unlikely to increase the risk to the foetus but may cross the placenta and cause haematological abnormalities in the newborn if administered after the second trimester. Breastfeeding is associated with a lower risk of exacerbation of MS after delivery. Family planning counselling for women with multiple sclerosis is crucial, as proper treatment planning and careful monitoring of the pregnancy course can contribute to the health of both mother and child.

09.12.2025